Role of aggressive surgical cytoreduction in advanced ovarian cancer / 부인종양
Journal of Gynecologic Oncology
; : 336-342, 2015.
Article
in En
| WPRIM
| ID: wpr-123432
Responsible library:
WPRO
ABSTRACT
Ovarian cancer is the eighth most frequent cancer in women and is the most lethal gynecologic malignancy worldwide. The majority of ovarian cancer patients are newly diagnosed presenting with advanced-stage disease. Primary cytoreductive surgery and adjuvant taxane- and platinum-based combination chemotherapy are the standard treatment for advanced ovarian cancer. A number of studies have consistently shown that successful cytoreductive surgery and the resultant minimal residual disease are significantly associated with survival in patients with this disease. Much has been written and even more debated regarding the competing perspectives of biology of ovarian cancer versus the value of aggressive surgical resection. This review will focus on the current evidences and outcomes supporting the positive impact of aggressive surgical effort on survival in the primary management of ovarian cancer.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Ovarian Neoplasms
/
Practice Patterns, Physicians'
/
Observer Variation
/
Randomized Controlled Trials as Topic
/
Retrospective Studies
/
Neoplasm, Residual
/
Evidence-Based Medicine
/
Cytoreduction Surgical Procedures
Type of study:
Observational_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Journal of Gynecologic Oncology
Year:
2015
Type:
Article